Ginkgo Bioworks Holdings Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $132.4M-41.7% YoYTTM through 30 Jun 2026
Net Income -$290.8MTTM through 30 Jun 2026
Free Cash Flow -$174.8MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | -190.3% |
| Operating Margin | -185.3% |
| Net Margin | -219.6% |
Returns
-70.6%ROE
-27.9%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio4.92x
Net Debt-$422.6Mnet cash position
Cash & Equivalents$84.5M
Quality Metrics
Altman Z-Score-8.79
Piotroski F-Score2 / 9
FCF Margin-132.0%
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2025: $170.2M
Diluted EPS-$5.64TTMFY2025: $-5.64
Dividend
No dividend
Capital Allocation
Capex Intensity3.4%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Cell Engineering | $125M | -3.0% | View detailsFocused on transitioning to autonomous research infrastructure (Nebula platform) and direct sales of platform tools. |
| Biosecurity | $37M | -30.0% | View detailsDivested on April 3, 2026 to Tower Biosecurity (Perimeter Systems) in exchange for a 20% equity stake. Classified as discontinued operations starting Q1 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.